Abcellera Biologics Inc
NASDAQ:ABCL

Watchlist Manager
Abcellera Biologics Inc Logo
Abcellera Biologics Inc
NASDAQ:ABCL
Watchlist
Price: 2.76 USD 1.47% Market Closed
Market Cap: 815.2m USD
Have any thoughts about
Abcellera Biologics Inc?
Write Note

Abcellera Biologics Inc
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Abcellera Biologics Inc
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Abcellera Biologics Inc
NASDAQ:ABCL
Cash Equivalents
$133.3m
CAGR 3-Years
-39%
CAGR 5-Years
67%
CAGR 10-Years
N/A
Arch Biopartners Inc
XTSX:ARCH
Cash Equivalents
CA$44k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Replicel Life Sciences Inc
XTSX:RP
Cash Equivalents
CA$15.2k
CAGR 3-Years
-32%
CAGR 5-Years
-9%
CAGR 10-Years
-41%
Innovotech Inc
XTSX:IOT
Cash Equivalents
CA$120.5k
CAGR 3-Years
-41%
CAGR 5-Years
39%
CAGR 10-Years
6%
No Stocks Found

Abcellera Biologics Inc
Glance View

Market Cap
802.7m USD
Industry
Life Sciences Tools & Services

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 386 full-time employees. The company went IPO on 2020-12-11. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.

ABCL Intrinsic Value
1.67 USD
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Abcellera Biologics Inc's Cash Equivalents?
Cash Equivalents
133.3m USD

Based on the financial report for Dec 31, 2023, Abcellera Biologics Inc's Cash Equivalents amounts to 133.3m USD.

What is Abcellera Biologics Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
67%

Over the last year, the Cash Equivalents growth was -66%. The average annual Cash Equivalents growth rates for Abcellera Biologics Inc have been -39% over the past three years , 67% over the past five years .

Back to Top